Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2T | Q9NPD8 | 1/20 | 1.00 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 1.00 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | STAT6 | P42226 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5009762 | 0.98 | UBE2T (0.96) | UBE2TASIC3LOXL2MAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL289191 | 0.98 | UBE2T (0.96) | UBE2TASIC3LOXL2MAPTSMN1; SMN2 | |
| Bromide SCHEMBL31511838 | 0.98 | UBE2T (0.96) | UBE2TASIC3LOXL2MAPTSMN1; SMN2 | |
| SCHEMBL3529770 | 0.84 | UBE2T (0.72) | UBE2TASIC3LOXL2MAPTSMN1; SMN2 | |
| SCHEMBL19372016 | 0.83 | UBE2T (0.70) | UBE2TASIC3MAPTSMN1; SMN2RAB9A | |
| SCHEMBL226465 | 0.83 | UBE2T (0.70) | UBE2TASIC3MAPTSMN1; SMN2RAB9A | |
| Hydrochloric Acid SCHEMBL12477869 | 0.82 | UBE2T (0.70) | UBE2TASIC3LOXL2MAPTSMN1; SMN2 | |
| SCHEMBL10743371 | 0.82 | UBE2T (0.67) | UBE2TASIC3LOXL2MAPTSMN1; SMN2 | |
| SCHEMBL10763327 | 0.81 | UBE2T (0.68) | UBE2TASIC3LOXL2MAPTSMN1; SMN2 | |
| Bromide SCHEMBL7601035 | 0.81 | UBE2T (0.68) | UBE2TASIC3MAPTSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627631-B1 | PYRROLIDINONES AS METAP2 INHIBITORS | MERCK PATENT GMBH (DE) | 2015-12-16 | — | — | EP | claimed |
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | claimed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| CN-102365337-A | Water based non-chromated primers for structural bonding applications | CYTEC TECH CORP | 2012-02-29 | — | — | CN | claimed |
| WO-2011073269-A1 | PIPERIDINE ARYL SULFONAMIDE DERIVATIVES AS KV1.3 MODULATORS | EVOTEC AG (DE) | 2011-06-23 | — | — | WO | claimed |
| US-20080207683-A1 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | claimed |
| WO-2008100622-A2 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| EP-1412328-B1 | DOLASTATIN 10 DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-10-04 | — | — | EP | claimed |
| CN-1553897-A | Dolastatin 10 derivatives | - | 2004-12-08 | — | — | CN | claimed |
| EP-1435352-A2 | 9-[(Substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines | Wyeth Holdings Corporation (US) | 2004-07-07 | — | — | EP | claimed |
| US-5466684-A | 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1995-11-14 | — | — | US | claimed |
| US-5442059-A | Antibiotics for mammalian and veterninary diseases | AMERICAN CYANAMID COMPANY (US) | 1995-08-15 | — | — | US | claimed |
| US-5420272-A | 7-(substituted)-8-(substituted)-9-](substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1995-05-30 | — | — | US | claimed |
| EP-0618190-A1 | 9-[(Substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1994-10-05 | — | — | EP | claimed |
| US-5328902-A | Antibiotics | AMERICAN CYANAMID CO. (US) | 1994-07-12 | — | — | US | claimed |
| EP-0582788-A1 | 7-(Substituted)-9- (substituted glycyl)-amido)-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1994-02-16 | — | — | EP | claimed |
| EP-0582789-A1 | Novel 7-(substituted)-8-(substituted)-9- (substituted glycyl)amido -6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1994-02-16 | — | — | EP | claimed |
| US-4914213-A | Indole derivatives and process for producing the same | FUJI PHOTO FILM CO., LTD. (JP) | 1990-04-03 | — | — | US | claimed |
| US-4707553-A | Indole derivatives and process for producing the same | FUJI PHOTO FILM CO., LTD. (JP) | 1987-11-17 | — | — | US | claimed |
| US-4435576-A | Process for the production of 2-amino-4-methyl-benzothiazole | LONZA LTD. (CH) | 1984-03-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207683-A1 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | UBE2T 1851/4885ASIC3 2449/4885LOXL2 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.